Tests glucose sensor use in pregnant women with type 2 diabetes
Compares a continuous glucose sensor with fingerstick checks in pregnant adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Continuous Glucose Monitor Use in Pregnancy
Key facts
- Where
- Worcester, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with type 2 diabetes who are early in a single pregnancy. It compares a continuous glucose monitor with fingerstick blood sugar checks.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Type 2 diabetes confirmed by lab tests: hemoglobin A1c 6.5% (48 mmol/mol) or higher, oral glucose tolerance test 200 mg/dL (11.1 mmol/L) or higher, or fasting plasma glucose 126 mg/dL (7 mmol/L) or higher. Pregnant with one baby, 14 weeks or less at the first obstetric visit.
Main reasons for not taking part
- Type 1 diabetes
- Gestational diabetes
- Pregnant with more than one baby
- Plans prenatal care or delivery outside UMMHC
- Cannot give informed consent
This trial only enrols pregnant participants. The registry sentence this rests on: 2) singleton gestation less than or equal to 14 weeks at initial obstetric visit
Read by machine on 9 November 2026.
Where in United States
- University of Massachusetts Memorial Medical CenterWorcester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Massachusetts, Worcester
- Trial code
- NCT05317585
- Record updated
- 3 August 2026
- Original description
The purpose of this study is to perform a randomized controlled trial among 180 pregnant women with type 2 diabetes mellitus (T2DM) comparing continuous glucose monitor (CGM) use to the standard of care of multiple daily fingerstick glucose monitoring and its impact on large for gestational age infants, maternal glycemic control, patient satisfaction, and additional adverse perinatal outcomes.Read full original descriptionShow less
Continuous Glucose Monitor Use and Perinatal Outcomes Among Pregnant Women With Type 2 Diabetes Mellitus: A Randomized Controlled Trial
The purpose of this study is to perform a randomized controlled trial among 180 pregnant women with type 2 diabetes mellitus (T2DM) comparing continuous glucose monitor (CGM) use to the standard of care of multiple daily fingerstick glucose monitoring and its impact on large for gestational age infants, maternal glycemic control, patient satisfaction, and additional adverse perinatal outcomes.
Inclusion: 1) age greater than or equal to 18 years old; 2) singleton gestation less than or equal to 14 weeks at initial obstetric visit; 3) established diagnosis of T2DM by laboratory criteria including hemoglobin A1c ≥6.5%, oral glucose tolerance test ≥200 mg/dL, or fasting plasma glucose ≥126 mg/dL; 4) receiving prenatal care at UMASS Memorial Health Care (UMMHC) and plans to deliver at UMMHC; 5) able and willing to provide informed consent.
Exclusion: 1) known diagnosis of type 1 diabetes or gestational diabetes; 2) plan to receive prenatal care or delivery outside of UMMHC; 3) inability to provide informed consent; 4) multifetal gestation.